PTC stocks have been the subject of various recent headlines, portraying an overall positive performance. With
Q2 earnings beat estimates, the growth trend was underscored by JPMorgan, maintaining a $53 target for PTC Therapeutics. Furthermore, the relative strength rating of PTC has notably risen to 83 as the investment attractiveness significantly improves.
GAMMA Investing LLC and
Congress Asset Management Co. MA have increased their stakes in PTC further solidifying investor confidence in the stock. Insider activity indicated both sales and purchases; while directors Janice Chaffin, Michal Katz, and Corinna Lathan sold company shares, CFO Pierre Gravier purchased 7,700 shares of PTC. Over the past five years, investors in NASDAQ:PTC have seen returns reach to 115%. However, Mizuho cut the stock rating to neutral citing 'sluggish demand trends.' PTC Therapeutics beat EPS and revenue for Q2 2024. Although European regulators rejected approval for Duchenne Drug resulting in the stock dipping momentarily, PTC stocks swiftly recovered indicating its resilience.
PTC Stocks News Analytics from Fri, 25 Aug 2023 07:00:00 GMT to Sat, 22 Jun 2024 08:40:11 GMT -
Rating 6
- Innovation 2
- Information 5
- Rumor 3
